Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Papillomavirus Infections 1COVID-19 1

Interventions

Cyclophosphamide 299Cisplatin 298Paclitaxel 257Radiotherapy 255Fluorouracil 234Carboplatin 234Docetaxel 230Doxorubicin 216Dexamethasone 166Gemcitabine 156Vincristine 147Etoposide 136Leucovorin 133Capecitabine 129Bevacizumab 129Prednisone 125Rituximab 118Methotrexate 118Cytarabine 110Filgrastim 99Trastuzumab 97Oxaliplatin 96pembrolizumab 83Pemetrexed 73Epirubicin 70Tamoxifen 69Drug Therapy 69Irinotecan 65Granulocyte Colony-Stimulating Factor 60Daunorubicin 58

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Completed × 2019-nCoV Vaccine mRNA-1273 × Clear all
NCT05119855 2026-02-05

Safety and Immunogenicity of 9-valent Human Papillomavirus (9vHPV) Vaccine Coadministered With Messenger Ribonucleic Acid (mRNA)-1273 Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) (COVID-19) Vaccine (V503-076)

Merck Sharp & Dohme LLC

Phase 3 Completed
165 enrolled 13 charts

COVID-19, Papillomavirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡